Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

100%

11 of 11 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

N/A

6(60.0%)

Phase 4

4(40.0%)

10Total

N/A(6)

Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06225362Not ApplicableCompleted

Quatera 700 vs. Centurion

Role: lead

NCT05464732Not ApplicableCompleted

Vivity IOL: Emmetropia Compared to Monovision.

Role: lead

NCT06229119Phase 4Completed

Vault Evaluation After ICL Implantation

Role: lead

NCT06229106Phase 4Completed

Symfony vs Vivity in Dim Light

Role: lead

NCT05069415Not ApplicableCompleted

Monofocal IOL Visual Outcomes When Targeting Mini Monovision

Role: lead

NCT04242875Completed

The Effects of Angle Kappa on Clinical Outcomes With the PanOptix Intraocular Lens

Role: lead

NCT03578276Phase 4Completed

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

Role: lead

NCT03771274Not ApplicableCompleted

Tecnis ZLB00 & Symfony Intraocular Lens Combination Outcomes

Role: lead

NCT03082599Not ApplicableCompleted

Symfony Toric Intraocular Lens Visual Outcomes

Role: lead

NCT02513745Not ApplicableCompleted

Conventional Surgery vs. Verion/VerifEye

Role: lead

NCT02515045Phase 4Completed

Dropless vs. Standard Drops Contralateral Eye Study

Role: lead

All 11 trials loaded